Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biotech Growth Trust (The)LSE:BIOG +2.46%30 Debt-to-Equity is 0.04 as of Mar. 2026, which is 20% below its 10-year median of 0.05. GuruFocus rates LSE:BIOG with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 944 Asset Management companies, Biotech Growth Trust (The) ranks better than 84.96% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Biotech Growth Trust (The)'s Debt-to-Equity or its related term are showing as below:
LSE:BIOG'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.05 Max: 0.13
Current: 0.04
During the past 13 years, the highest Debt-to-Equity Ratio of Biotech Growth Trust (The) was 0.13. The lowest was 0.03. And the median was 0.05.
LSE:BIOG's Debt-to-Equity is ranked better than 84.96% of 944
companies
in the Asset Management industry
Industry Median: 0.21
vs LSE:BIOG: 0.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Biotech Growth Trust (The) Debt-to-Equity Related Terms
Biotech Growth Trust (The) Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:BIOG vs BLK, BX, KKR: Debt-to-Equity Comparison
For the Asset Management subindustry, Biotech Growth Trust (The)'s Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotech Growth Trust (The) Debt-to-Equity vs Asset Management Industry
For the Asset Management industry and Financial Services sector, Biotech Growth Trust (The)'s Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Biotech Growth Trust (The)'s Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotech Growth Trust (The) (LSE:BIOG) has a Debt-to-Equity of 0.04 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Biotech Growth Trust (The) and its competitors. This is 20% below median its historical median of 0.05. Over the past decade, Biotech Growth Trust (The)'s Debt-to-Equity has ranged from 0.03 to 0.13. According to the industry distribution chart, Biotech Growth Trust (The) ranks #142 out of 944 companies in the Asset Management industry, placing it in the top 15%.
Is Biotech Growth Trust (The)'s Debt-to-Equity too high?
Biotech Growth Trust (The)'s current Debt-to-Equity of 0.04 is 20% below median its 10-year median of 0.05. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 0.13. The Asset Management industry median Debt-to-Equity is 0.21. Biotech Growth Trust (The)'s value of 0.04 is 81% below this industry median. Based on the distribution chart, Biotech Growth Trust (The) ranks #142 out of 944 companies in the Asset Management industry, which is in the top quartile — a strong position relative to peers. Overall, Biotech Growth Trust (The) has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Biotech Growth Trust (The)'s Debt-to-Equity compare to BLK and BX?
According to the Asset Management industry distribution chart, Biotech Growth Trust (The) ranks #142 out of 944 companies for Debt-to-Equity. This places Biotech Growth Trust (The) in the top 15% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.21. Biotech Growth Trust (The)'s value of 0.04 is 81% below this benchmark. Historically, Biotech Growth Trust (The)'s own Debt-to-Equity has ranged from 0.03 to 0.13 over the past decade. While the company's 10-year median is 0.05 vs. the industry median of 0.21, Biotech Growth Trust (The) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for an Asset Management company?
The median Debt-to-Equity among Asset Management companies is 0.21, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biotech Growth Trust (The)'s current Debt-to-Equity of 0.04 is 81% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Biotech Growth Trust (The) and its competitors. For the Asset Management industry, the median Debt-to-Equity is 0.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biotech Growth Trust (The)'s current Debt-to-Equity is 0.04, which is 20% below median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotech Growth Trust (The) stock overvalued right now?
Biotech Growth Trust (The) (LSE:BIOG) has a current Debt-to-Equity of 0.04. The current Debt-to-Equity is 0.04, which is 20% below median its 10-year median of 0.05 and 81% below the Asset Management industry median of 0.21. Biotech Growth Trust (The)'s overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Biotech Growth Trust (The) (LSE:BIOG), the current Debt-to-Equity is 0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biotech Growth Trust (The) PLC is an externally managed investment trust. Its business objective is to provide its investors with capital appreciation by investing in the biotechnology industry around the world.
30GF Score
Get the complete analysis for LSE:BIOG
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BIOG has been successfully added to your 
